Currently, the application forms of PD immunotherapy are diverse, primarily including passive immunity, such as monoclonal antibodies targeting α-synuclein, active immunization vaccines, and innate immune regulators (5, 6). The gene discussed is SNCA; the disease is Parkinson disease.